2. Search Result
Search Result
Results for "

anti-obesity agent

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

2

Peptides

9

Natural
Products

2

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-N4103
    Fucosterol
    2 Publications Verification

    		 PARP Endogenous Metabolite Metabolic Disease Cancer
    Fucosterol is a sterol isolated from algae, seaweed or diatoms. Fucosterol exhibits various biological activities, including antioxidant, anti-adipogenic, blood cholesterol reducing, anti-diabetic and anti-cancer activities . Fucosterol regulates adipogenesis via inhibition of PPARα and C/EBPα expression and can be used for anti-obesity agents development research .
    Fucosterol
  • HY-N0547
    Nomilin
    2 Publications Verification

    		 Others Metabolic Disease
    Nomilin is a limonoid compound obtained from the extracts of citrus fruits. Nomilin is an anti-obesity and anti-hyperglycemic agent .
    Nomilin
  • HY-14472
    Tesofensine

    NS-2330

    		 Dopamine Transporter Serotonin Transporter Metabolic Disease
    Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC50=6.5 nM), norepinephrine (NE;IC50=1.7 nM), and serotonin (5-HT;IC50=11 nM), and with potentials as an anti-obesity agent . Tesofensine is a CNS acting anti-obesity agent .
    Tesofensine
  • HY-145605
    Vutiglabridin

    HSG4112

    		 Reactive Oxygen Species (ROS) Bacterial PPAR Metabolic Disease
    Vutiglabridin (HSG4112), a racemic compound, is a potent anti-obesity agent . Vutiglabridin, an optimized structural analog of Glabridin, markedly supersedes Glabridin in weight reduction efficacy and chemical stability .
    Vutiglabridin
  • HY-14471
    Cetilistat
    1 Publications Verification

    ATL-962

    		 Lipase Metabolic Disease
    Cetilistat (ATL-962), an inhibitor of pancreatic lipase, acts as an effective anti-obesity agent. Cetilistat inhibits rat and human pancreatic lipase activity with IC50s of 54.8 nM, and 5.95 nM, respectively .
    Cetilistat
  • HY-126956
    Porphyra 334

    		Reactive Oxygen Species (ROS) MMP Collagen PPAR DNA/RNA Synthesis Apoptosis Caspase Metabolic Disease Inflammation/Immunology
    Porphyra 334 is a carnosine-like amino acid and a natural photoprotective agent and antioxidant. Porphyra-334 exerts its photoprotective effects by scavenging ROS, inhibiting the expression and activity of MMP-1/8, and promoting the synthesis of collagen and elastin. Porphyra 334 effectively inhibits linoleic acid oxidation induced by alkyl radicals (AAPH) and singlet oxygen. Porphyra 334 has anti-obesity potential by inhibiting the expression of PPARγ2 and C/EBPα. Porphyra 334 protects cells against UV-induced DNA damage and apoptosis by inhibiting the activation of caspase-3 .
    Porphyra 334
  • HY-N7347
    (-)-Hydroxycitric acid lactone

    Garcinia lactone

    		 ATP Citrate Lyase Metabolic Disease
    (-)-Hydroxycitric acid lactone (Garcinia lactone) is an anti-obesity agent and a popular weight loss food supplement. (-)-Hydroxycitric acid lactone is a potent inhibitor of ATP-citrate lyase. (-)-Hydroxycitric acid lactone catalyzes the extramitochondrial cleavage of citrate to oxaloacetate and acetyl-CoA, limits the availability of acetyl-CoA units required for fatty acid synthesis .
    (-)-Hydroxycitric acid lactone
  • HY-103249
    Reutericyclin

    Reutericycline

    		 Bacterial Infection Metabolic Disease
    Reutericyclin (Reutericycline) is an orally active antibacterial and anti-obesity agent that selectively inhibits Gram-positive bacteria. By selectively dissipating transmembrane potential, Reutericyclin exerts non-lytic bactericidal or bacteriostatic activity against pathogens such as Clostridium difficile and Staphylococcus aureus, and rapidly kills vegetative cells and spores of Clostridium difficile. Reutericyclin possesses favorable properties including resistance to enzymatic hydrolysis, iron-chelating function, and poor absorption by colonic epithelium. Reutericyclin not only eradicates staphylococcal biofilms and inhibits drug-resistant strains, but also counteracts Risperidone (HY-11018)-induced weight gain by inducing changes in gut microbiota composition and restoring energy utilization efficiency. Reutericyclin can be used in research related to Clostridium difficile infection, Risperidone-induced weight gain, and staphylococcal superficial skin infections .
    Reutericyclin
  • HY-161305
    SE-7552

    		HDAC Metabolic Disease Cancer
    SE-7552, a 2-(difluoromethyl)-1,3,4-oxadiazole (DFMO) derivative, is an orally active, highly selective, non-hydroxamate HDAC6 inhibitor with an IC50 of 33 nM. SE-7552 is greater than 850-fold selectivity versus all other known HDAC isozymes. SE-7552 is capable of blocking multiple myeloma growth in vivo. SE-7552 acts as an anti-obesity agent in diet-induced obese mice .
    SE-7552
  • HY-N14035
    Garcinia cambogia extract

    		FABP PPAR Metabolic Disease
    Garcinia cambogia extract is an orally active anti-obesity agent . Garcinia cambogia extract upregulates the gene expression of aP2, SREBP1c, PPARγ2 and C/EBPα. Garcinia cambogia extract reduces the rate of body weight gain, visceral fat accumulation, lipid levels in blood and liver, as well as plasma insulin and leptin levels . Garcinia cambogia extract ameliorates high-fat diet-induced obesity .
    Garcinia cambogia extract
  • HY-168467
    Anti-obesity agent 1

    		PPAR GLUT Metabolic Disease
    Anti-obesity agent 1 (compound 4) shows potential for enhancing lipolysis, exhibiting their anti-obesity properties .
    Anti-obesity agent 1
  • HY-P10380
    palm11-PrRP31

    		Neuropeptide FF Receptor Neurological Disease Metabolic Disease
    palm11-PrRP31 is a lipidized endogenous appetite inhibitory neuropeptide (PrRP) analogue. palm11-PrRP31 is GPR10 (EC50=39 pM) and NPFF-R2 effective dual agonists. palm11-PrRP31 is able to mimic the natural function of PrRP by binding to these receptors to reduce food intake. palm11-PrRP31 can be used as a potential anti-obesity agent and for the study of neuropeptide-receptor interaction .
    palm11-PrRP31
  • HY-14472R
    Tesofensine (Standard)

    NS-2330 (Standard)

    		 Dopamine Transporter Serotonin Transporter Reference Standards Metabolic Disease
    Tesofensine (Standard) is the analytical standard of Tesofensine. This product is intended for research and analytical applications. Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC50=6.5 nM), norepinephrine (NE;IC50=1.7 nM), and serotonin (5-HT;IC50=11 nM), and with potentials as an anti-obesity agent . Tesofensine is a CNS acting anti-obesity agent .
    Tesofensine (Standard)
  • HY-117167
    KB-141

    		Thyroid Hormone Receptor Cancer
    KB-141 is a potent and selective TRβ agonist. The IC50 values are 23.9 nM and 3.3 nM for binding affinities from displacement of T3 from hTRα1 and hTRβ1, respectively. KB-141 has anti-obesity, anti-diabetic, and lipid-lowering effects?and can be used as an anti-cholesteremic agent in vivo .
    KB-141
  • HY-N4103R
    Fucosterol (Standard)

    		Reference Standards PARP Endogenous Metabolite Metabolic Disease Cancer
    Fucosterol (Standard) is the analytical standard of Fucosterol. This product is intended for research and analytical applications. Fucosterol is a sterol isolated from algae, seaweed or diatoms. Fucosterol exhibits various biological activities, including antioxidant, anti-adipogenic, blood cholesterol reducing, anti-diabetic and anti-cancer activities . Fucosterol regulates adipogenesis via inhibition of PPARα and C/EBPα expression and can be used for anti-obesity agents development research .
    Fucosterol (Standard)
  • HY-A0175
    Butriptyline

    Butriptylene

    		 5-HT Receptor Neurological Disease
    Butriptyline (Butriptylene) is an orally active tricyclic antidepressant that slightly enhances central 5-HT effects. Butriptyline does not inhibit brain norepinephrine uptake. Butriptyline can be used for depression research .
    Butriptyline
  • HY-136124
    Cetilistat impurity 1

    		Drug Metabolite Others
    Cetilistat impurity 1 is an impurity of Cetilistat. Cetilistat, an inhibitor of pancreatic lipase, acts as an effective anti-obesity agent. Cetilistat inhibits rat and human pancreatic lipase activity with IC50s of 54.8 nM, and 5.95 nM, respectively .
    Cetilistat impurity 1
  • HY-P10380A
    palm11-PrRP31 TFA

    		Neuropeptide FF Receptor Neurological Disease Metabolic Disease
    palm11-PrRP31 TFA is a lipidized endogenous appetite inhibitory neuropeptide (PrRP) analogue. palm11-PrRP31 TFA is GPR10 (EC50=39 pM) and NPFF-R2 effective dual agonists. palm11-PrRP31 TFA is able to mimic the natural function of PrRP by binding to these receptors to reduce food intake. palm11-PrRP31 TFA can be used as a potential anti-obesity agent and for the study of neuropeptide-receptor interaction .
    palm11-PrRP31 TFA
  • HY-149593
    VU0506013

    		Neuropeptide Y Receptor Metabolic Disease
    VU0506013 is a selective positive allosteric modulator of Y4R (KB = 34.9 nM). VU0506013 can be used in the development of anti-obesity agents targeting Y4R .
    VU0506013
  • HY-110034
    Didesmethylsibutramine hydrochloride

    BTS 54-505

    		 Drug Metabolite Metabolic Disease
    Didesmethylsibutramine (BTS 54-505) hydrochloride is the primary amine metabolite of Sibutramine (antidepressant and anti-obesity agent). Didesmethylsibutramine hydrochloride inhibits NMDA-evoked activity. Didesmethylsibutramine hydrochloride is also a reuptake inhibitor. Didesmethylsibutramine hydrochloride induces thermogenesis .
    Didesmethylsibutramine hydrochloride
  • HY-N0547R
    Nomilin (Standard)

    		Apoptosis IKK TNF Receptor Reference Standards Metabolic Disease
    Nomilin (Standard) is the analytical standard of Nomilin. This product is intended for research and analytical applications. Nomilin is a limonoid compound obtained from the extracts of citrus fruits. Nomilin is an anti-obesity and anti-hyperglycemic agent .
    Nomilin (Standard)
  • HY-161899
    MCHR1 antagonist 4

    		MCHR1 (GPR24) Others
    MCHR1 antagonist 4 (Compound 2m) is a blood-brain barrier permeable MCHR1 antagonist with Ki values of 0.74 nM and 0.76 nM for hMCHR1 and rMCHR1, respectively. MCHR1 antagonist 4 is also an effective anti-obesity agent .
    MCHR1 antagonist 4
  • HY-110034R
    Didesmethylsibutramine hydrochloride (Standard)

    BTS 54-505 (Standard)

    		 Drug Metabolite Reference Standards Metabolic Disease
    Didesmethylsibutramine (hydrochloride) (Standard) is the analytical standard of Didesmethylsibutramine (hydrochloride). This product is intended for research and analytical applications. Didesmethylsibutramine (BTS 54-505) hydrochloride is the primary amine metabolite of Sibutramine (antidepressant and anti-obesity agent). Didesmethylsibutramine hydrochloride inhibits NMDA-evoked activity. Didesmethylsibutramine hydrochloride is also a reuptake inhibitor. Didesmethylsibutramine hydrochloride induces thermogenesis .
    Didesmethylsibutramine hydrochloride (Standard)
  • HY-14471R
    Cetilistat (Standard)

    ATL-962 (Standard)

    		 Lipase Reference Standards Metabolic Disease
    Cetilistat (Standard) is the analytical standard of Cetilistat. This product is intended for research and analytical applications. Cetilistat (ATL-962), an inhibitor of pancreatic lipase, acts as an effective anti-obesity agent. Cetilistat inhibits rat and human pancreatic lipase activity with IC50s of 54.8 nM, and 5.95 nM, respectively .
    Cetilistat (Standard)
  • HY-162703
    Lipid-lowering agent-2

    		AMPK Metabolic Disease
    Lipid-lowering agent-2 (Compound 14d) is an orally active lipid-lowering agent with an EC50 of 0.06 μM. Lipid-lowering agent-2 inhibits the lipid synthesis, activates the AMPK signaling pathway, and exhibits anti-obesity effect. Lipid-lowering agent-2 inhibits food intake, improves the glucose metabolism, and reduces the body weight and adipose tissue in high-fat diet (HFD)-induced obese mice .
    Lipid-lowering agent-2
  • HY-N7347R
    (-)-Hydroxycitric acid lactone (Standard)

    Garcinia lactone (Standard)

    		 Reference Standards ATP Citrate Lyase Metabolic Disease
    (-)-Hydroxycitric acid lactone (Standard) is the analytical standard of (-)-Hydroxycitric acid lactone. This product is intended for research and analytical applications. (-)-Hydroxycitric acid lactone (Garcinia lactone) is an anti-obesity agent and a popular weight loss food supplement. (-)-Hydroxycitric acid lactone is a potent inhibitor of ATP-citrate lyase. (-)-Hydroxycitric acid lactone catalyzes the extramitochondrial cleavage of citrate to oxaloacetate and acetyl-CoA, limits the availability of acetyl-CoA units required for fatty acid synthesis .
    (-)-Hydroxycitric acid lactone (Standard)
  • HY-13766
    Timcodar

    VX-853

    		 PPAR Others
    Timcodar is a macrolide agent, and studies have shown that during adipogenesis, timcodar can significantly inhibit fat accumulation, with an effect similar to that of rapamycin. However, unlike rapamycin, timcodar does not cause immunosuppression and glucose resistance. In addition, timcodar can effectively inhibit the adipogenic transcriptional regulators PPAR?? and C/EBP??, thereby inhibiting genes involved in fat accumulation. These studies lay the foundation for timcodar as a potential anti-obesity therapy, as obesity is becoming a global epidemic.
    Timcodar
  • HY-118709
    Ro 23-7637

    		Drug Derivative Metabolic Disease
    Ro 23-7637 is an orally active, efficacious antiobesity agent .
    Ro 23-7637
  • HY-12191
    A-331440

    		Histamine Receptor Metabolic Disease
    A-331440 is a potent and selective histamine H3 receptor antagonist that regulates neurotransmitter release by inhibiting presynaptic H3 receptors. In preclinical studies involving mice on a high-fat diet, A-331440 demonstrated dose-dependent effects on weight reduction and fat loss. At 5 mg/kg, it effectively decreased body weight comparable to dexfenfluramine, while at 15 mg/kg, it significantly reduced body fat and improved insulin tolerance, similar to mice on a low-fat diet. These findings suggest that A-331440 holds promise as an antiobesity agent by modulating histaminergic pathways involved in food intake and metabolic regulation .
    A-331440
  • HY-14472S
    Tesofensine-d5

    NS-2330-d5

    		 Isotope-Labeled Compounds Serotonin Transporter Dopamine Transporter Metabolic Disease
    Tesofensine-d5 (NS-2330-d5) is the deuterium labeled Tesofensine (HY-14472). Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC50=6.5 nM), norepinephrine (NE;IC50=1.7 nM), and serotonin (5-HT;IC50=11 nM), and with potentials as an anti-obesity agent. Tesofensine is a CNS acting anti-obesity agent.
    Tesofensine-d5
  • HY-14472S1
    Tesofensine-13C,d3

    NS-2330-13C,d3

    		 Isotope-Labeled Compounds Serotonin Transporter Dopamine Transporter Metabolic Disease
    Tesofensine- 13C,d3 (NS-2330- 13C,d3) is the deuterium and 13C-labeled Tesofensine (HY-14472). Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC50=6.5 nM), norepinephrine (NE;IC50=1.7 nM), and serotonin (5-HT;IC50=11 nM), and with potentials as an anti-obesity agent . Tesofensine is a CNS acting anti-obesity agent .
    Tesofensine-13C,d3
  • HY-A0175A
    Butriptyline hydrochloride

    Butriptylene hydrochloride

    		 5-HT Receptor Neurological Disease
    Butriptyline (Butriptylene) hydrochloride is an orally active tricyclic antidepressant that slightly enhances central 5-HT effects. Butriptyline hydrochloride does not inhibit brain norepinephrine uptake. Butriptyline hydrochloride can be used for depression research .
    Butriptyline hydrochloride
  • HY-122165A
    LY-79771 hydrochloride

    		Endogenous Metabolite Metabolic Disease
    LY-79771 hydrochloride is a phenethanolamine antiobesity agent that exhibits activity in preventing fat regain following energy deprivation. LY-79771 hydrochloride effectively aids in weight management and promotes metabolic health.
    LY-79771 hydrochloride

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: